Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2599078 | 0.88 | PIM1 (0.36) | DAPK3NTRK1PIM1FLT3GSK3B | |
| SCHEMBL2599076 | 0.88 | PIM1 (0.36) | DAPK3NTRK1PIM1FLT3GSK3B | |
| SCHEMBL1805029 | 0.88 | PIM1 (0.36) | DAPK3NTRK1PIM1FLT3GSK3B | |
| SCHEMBL860932 | 0.88 | PIM1 (0.36) | DAPK3NTRK1PIM1FLT3GSK3B | |
| SCHEMBL1804241 | 0.86 | PIM1 (0.47) | DAPK3NTRK1PIM1FLT3GSK3B | |
| SCHEMBL1804240 | 0.86 | PIM1 (0.47) | DAPK3NTRK1PIM1FLT3GSK3B | |
| SCHEMBL1804237 | 0.86 | PIM1 (0.47) | DAPK3NTRK1PIM1FLT3GSK3B | |
| SCHEMBL1804970 | 0.85 | CLK4 (0.33) | DAPK3NTRK1PIM1FLT3GSK3B | |
| SCHEMBL1804971 | 0.85 | CLK4 (0.33) | DAPK3NTRK1PIM1FLT3GSK3B | |
| SCHEMBL1804967 | 0.85 | CLK4 (0.33) | DAPK3NTRK1PIM1FLT3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571353-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2017-08-09 | — | — | EP | disclosed |
| US-8846951-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | ERN1 4806/4885DAPK3 1203/4885NTRK1 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.